Structure-centered design of lipid-based nanocarriers to overcome biological barriers
Source abstract
Abstract
As technology has evolved in response to pressing human challenges, drug delivery systems (DDSs) have also evolved to overcome complex biological barriers. Particularly, the continuous development of therapeutic strategies has enabled the integration of nanotechnology, leading to the emergence of diverse nanoscale DDSs. Concerns about the potential toxicity of nanomedicines diverted attention to lipid-based nanocarriers (LBNs), regarded as safer and more biocompatible platforms. In this review, the structural evolution of LBNs is categorized into three stages according to the increasing functional complexity required to address biological barriers, providing a framework to understand how designs advanced with physiological demands. This trajectory encompasses emulsions and LBNs, with each stage advanced by strategies such as lipid composition tuning, surface functionalization, biomimetic construction, and hybridization with other platforms. Over a few decades, this transition has described that the progression of LBNs reflects not merely chronological advances but a stepwise evolution of structural adaptations shaped by biological barriers. This analytical perspective is presented through a comprehensive discussion of the structural strategies utilized in recent LBN research. Consequently, structural evolution provides a foundation for refining design approaches in drug delivery and achieving improved therapeutic outcomes. • Drug delivery systems have evolved in response to challenges in biological barriers. • The structure of nanocarriers is essential for the coordination of their functions. • Structural design is an expression of design intent to overcome biological barriers. • Structure-centered designs are key to the development of next-generation DDSs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Surface modification of lipid-based nanocarriers: a potential approach to enhance targeted drug delivery10.1021/acsomega.2c05976 ↗
2. Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization10.3389/fmolb.2020.587012 ↗
3. Overcoming key biological barriers to cancer drug delivery and efficacy10.1016/j.jconrel.2017.09.016 ↗
4. Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system10.1111/jphp.12550 ↗
5. Lipid nanoparticles for enhancing oral bioavailability10.1039/D4NR01487A ↗
6. Optimized nanoparticles for enhanced oral bioavailability of a poorly soluble drug: solid lipid nanoparticles versus nanostructured lipid carriers10.2174/2211738510666220210110003 ↗
7. Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma10.7150/thno.35972 ↗
8. PEG− doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity10.1021/bc040241m ↗
9. PEGylated anti‐MUC1 aptamer‐doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells10.1002/mabi.201100173 ↗
10. Biophysics of cell membrane lipids in cancer drug resistance: implications for drug transport and drug delivery with nanoparticles10.1016/j.addr.2013.09.004 ↗
11. Gastroretentive drug delivery technologies: current approaches and future potential
12. Dual-modified nanoparticles overcome sequential absorption barriers for oral insulin delivery10.1016/j.jconrel.2021.11.045 ↗
13. Carriers break barriers in drug delivery: endocytosis and endosomal escape of gene delivery vectors10.1021/acs.accounts.9b00177 ↗
14. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation10.3109/10717544.2016.1165314 ↗
15. Prodrug strategy to address impaired oral absorption of a weakly basic TYK2 inhibitor caused by a gastric acid-reducing agent10.1021/acs.jmedchem.4c02219 ↗
16. Design and optimization of chitosan-coated solid lipid nanoparticles containing insulin for improved intestinal permeability using piperine10.1016/j.ijbiomac.2024.135849 ↗
17. Chylomicron-pretended nano-bio self-assembling vehicle to promote lymphatic transport and GALTs target of oral drugs10.1016/j.biomaterials.2018.10.012 ↗
18. Oral delivery of stabilized lipid nanoparticles for nucleic acid therapeutics10.1007/s13346-024-01709-4 ↗
19. Ionic liquid-coated lipid nanoparticles increase siRNA uptake into CNS targets10.1039/D3NA00699A ↗
20. Inhalable nano formulation of cabazitaxel: a comparative study with intravenous route10.1002/mabi.202400567 ↗
21. Toward understanding the purely geometric effects of silver nanoparticles on potential application as ocular therapeutics via treatment of bacterial keratitis10.1016/j.msec.2020.111497 ↗
22. Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration10.1016/j.carbon.2022.09.045 ↗
23. Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma10.1039/C7TB01217A ↗
24. Design of highly adhesive urchin‐like gold nanostructures for effective topical drug administration and symptomatic relief of corneal dryness10.1002/sstr.202570006 ↗
25. Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment, Beni-buef Univ. J
26. Solid lipid nanoparticles of curcumin designed for enhanced bioavailability and anticancer efficiency10.1021/acsomega.2c04407 ↗
27. Liver-specific ionizable lipid nanoparticles mediated efficient RNA interference to clear “bad cholesterol,”10.2147/IJN.S434908 ↗
28. Solid lipid-based nanoparticulate system for sustained release and enhanced in-vitro cytotoxic effect of 5-fluorouracil on skin melanoma and squamous cell carcinoma
29. Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications10.3390/pharmaceutics15030772 ↗
30. Sustained release curcumin loaded solid lipid nanoparticles10.15171/apb.2016.04 ↗
31. Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer10.1038/s41598-020-73218-6 ↗
32. Nitric oxide delivery using nanostructures and its biomedical applications
33. Size, shape, charge and “stealthy” surface: carrier properties affect the drug circulation time in vivo
34. Experimental and theoretical explorations of nanocarriers' multistep delivery performance for rational design and anticancer prediction10.1126/sciadv.aba2458 ↗
35. Acidification-induced structure evolution of lipid nanoparticles correlates with their in vitro gene transfections10.1021/acsnano.2c06213 ↗
36. Nanoparticles as drug delivery systems10.1016/S1734-1140(12)70901-5 ↗
37. Drug delivery by red blood cells10.1002/iub.478 ↗
38. Introductory chapter: drug delivery concepts
39. Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form10.1016/j.jddst.2018.08.019 ↗
40. Nanoemulsion: an advanced mode of drug delivery system10.1007/s13205-014-0214-0 ↗
41. Facile methodology of nanoemulsion preparation using oily polymer for the delivery of poorly soluble drugs10.1007/s13346-019-00703-5 ↗
42. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation10.3109/08982100903347923 ↗
43. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery10.1016/j.colsurfb.2014.09.029 ↗
44. Advances in nanotechnology for enhancing the solubility and bioavailability of poorly soluble drugs10.2147/DDDT.S447496 ↗
45. Improving drug solubility for oral delivery using solid dispersions10.1016/S0939-6411(00)00076-X ↗
46. Stable drug encapsulation in micelles and microemulsions10.1016/j.ijpharm.2007.08.057 ↗
47. Biocompatible nanoemulsions based on hemp oil and less surfactants for oral delivery of baicalein with enhanced bioavailability10.2147/IJN.S131167 ↗
48. Double w/o/w self-nano emulsifying drug delivery system of imatinib mesylate for colon cancer treatment10.1016/j.molliq.2021.117368 ↗
49. Advances of microemulsion and its applications for improved oil recovery10.1016/j.cis.2021.102527 ↗
50. Microemulsions: unique properties, pharmacological applications, and targeted drug delivery10.3389/fnano.2021.754889 ↗
51. Development and characterization of a biocompatible soybean oil-based microemulsion for the delivery of poorly water-soluble drugs10.1002/jps.24555 ↗
52. Development and in vitro–in vivo evaluation of a water-in-oil microemulsion formulation for the oral delivery of troxerutin10.3109/03639045.2015.1047849 ↗
53. Enhanced lymphatic delivery of methotrexate using W/O/W nanoemulsion: in vitro characterization and pharmacokinetic study10.3390/pharmaceutics12100978 ↗
54. Controlled drug delivery systems: current status and future directions10.3390/molecules26195905 ↗
55. Toxic effects of 5 organic solvents on Euglena agilis10.11626/KJEB.2015.33.1.045 ↗
56. Solution or suspension–does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug10.1016/j.ejpb.2017.04.023 ↗
57. Risk of liver injury associated with intravenous lipid emulsions: a prescription sequence symmetry analysis
58. Innovations in nanoemulsion technology: enhancing drug delivery for oral, parenteral, and ophthalmic applications10.3390/pharmaceutics16101333 ↗
59. Design of liposomes as drug delivery system for therapeutic applications10.1016/j.ijpharm.2021.120571 ↗
60. Therapeutic hydrogel sheets programmed with multistage drug delivery for effective treatment of corneal abrasion10.1016/j.cej.2021.132409 ↗
61. Microfluidic fabrication of oleosin-coated liposomes as anticancer drug carriers with enhanced sustained drug release10.3390/ma17225550 ↗
62. Liposome-based delivery of biological drugs10.1016/j.cclet.2021.08.020 ↗
63. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects10.1016/j.ijpharm.2016.03.031 ↗
64. Increased encapsulation efficiency of methotrexate in liposomes for rheumatoid arthritis therapy10.3390/biomedicines8120630 ↗
65. Improved in vitro corneal delivery of a thrombospondin-1-derived peptide using a liposomal formulation10.1016/j.exer.2017.12.002 ↗
66. The suitability of liposomes for the delivery of hydrophobic drugs–a case study with curcumin10.1016/j.ejpb.2019.04.013 ↗
67. Effect of liposomal formulation of ascorbic acid on corneal permeability10.1038/s41598-023-29290-9 ↗
68. Multiscale combined techniques for evaluating emulsion stability: a critical review10.1016/j.cis.2022.102813 ↗
69. Safety of surfactant excipients in oral drug formulations10.1016/j.addr.2023.115086 ↗
70. Self-emulsifying drug delivery systems (SEDDS): transition from liquid to solid—a comprehensive review of formulation, characterization, applications, and future trends10.3390/pharmaceutics17010063 ↗
71. Liposome-based formulation for intracellular delivery of functional proteins10.1038/mtna.2015.17 ↗
72. Pharmacokinetic and pharmacodynamic modulations of therapeutically active constituents from orally administered nanocarriers along with a glimpse of their advantages and limitations
73. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems10.3390/pharmaceutics10020057 ↗
74. Liposome fractionation and size analysis by asymmetrical flow field-flow fractionation/multi-angle light scattering: influence of ionic strength and osmotic pressure of the carrier liquid10.1016/j.chemphyslip.2009.10.009 ↗
75. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs10.1517/17425247.2014.884557 ↗
76. Recent progress in diatom biosilica: a natural nanoporous silica material as sustained release carrier10.3390/pharmaceutics15102434 ↗
77. On the structure, stability, and cell uptake of nanostructured lipid carriers for drug delivery10.1021/acs.molpharmaceut.4c00392 ↗
78. Importance of encapsulation stability of nanocarriers with high drug loading capacity for increasing in vivo therapeutic efficacy10.1021/acs.biomac.8b00589 ↗
79. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art10.1016/S0939-6411(00)00087-4 ↗
80. Solid lipid nanoparticles (SLNs) gels for topical delivery of aceclofenac in vitro and in vivo evaluation10.2174/156720181006131125150023 ↗
81. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application10.15171/apb.2015.043 ↗
82. Optimization of the conditions of solid lipid nanoparticles (SLN) synthesis10.3390/molecules27072202 ↗
83. Solid lipid nanoparticles10.3390/encyclopedia2020063 ↗
84. Stability of paclitaxel-loaded solid lipid nanoparticles in the presence of 2-hydoxypropyl-β-cyclodextrin10.1007/s12272-016-0753-5 ↗
85. Enhanced stability and dermal delivery of hydroquinone using solid lipid nanoparticles10.1016/j.colsurfb.2015.10.041 ↗
86. Preparation, characterization and in vitro cytotoxicity of fenofibrate and nabumetone loaded solid lipid nanoparticles10.1016/j.msec.2019.110184 ↗
87. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems10.1039/D0RA03491F ↗
88. Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations10.3390/pharmaceutics13040437 ↗
89. Enhanced storage stability of solid lipid nanoparticles by surface modification of comb-shaped amphiphilic inulin derivatives10.1016/j.colsurfb.2019.05.061 ↗
90. Effect of binary solid lipid matrix of wax and triglyceride on lipid crystallinity, drug-lipid interaction and drug release of ibuprofen-loaded solid lipid nanoparticles (SLN) for dermal delivery10.1016/j.jcis.2017.05.038 ↗
91. Solid lipid nanoparticles (SLN) as a novel drug delivery system: a theoretical review
92. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration10.3109/10717544.2014.898110 ↗
93. Construction of chitosan oligosaccharide-coated nanostructured lipid carriers for the sustained release of strontium ranelate
94. Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy10.3109/10837450.2014.996900 ↗
95. Dependence of the core–shell structure on the lipid composition of nanostructured lipid carriers: implications for drug carrier design10.1021/acsanm.2c02214 ↗
96. Nanostructured lipid carriers: promising delivery systems for encapsulation of food ingredients
97. Natural lipids-based NLC containing lidocaine: from pre-formulation to in vivo studies10.1016/j.ejps.2017.05.060 ↗
98. The influence of NLC composition on curcumin loading under a physicochemical perspective and in vitro evaluation10.1016/j.colsurfa.2020.125070 ↗
99. pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation10.2147/IJN.S184355 ↗
100. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs10.4103/2230-973X.167661 ↗